Search results for "CAPE"

showing 10 items of 1938 documents

Bevacizumab efficacy in metastatic colorectal cancer is dependent on primary tumor resection.

2014

Purpose Bevacizumab plus fluoropyrimidine-based chemotherapy is standard treatment for first-line and second-line metastatic colorectal cancer (mCRC). However, to date, there is no current biomarker predictive for the benefit of bevacizumab use for these patients. Preclinical data suggest that the presence of the primary tumor could be involved in less efficient antitumor activity of antiangiogenic agents, but no clinical data currently support this hypothesis. Methods We performed a retrospective analysis of factors associated with overall survival (OS) in a study cohort of 409 mCRC patients. Univariate and multivariate Cox proportional hazard regression models were used to assess the infl…

OncologyAdultMalemedicine.medical_specialtyBevacizumabOrganoplatinum CompoundsColorectal cancerAdenocarcinomaAntibodies Monoclonal HumanizedIrinotecanDeoxycytidineCapecitabineSurgical oncologyInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProspective StudiesNeoplasm MetastasisSurvival rateCapecitabineAgedNeoplasm StagingRetrospective StudiesAged 80 and overColorectal Cancerbusiness.industryMiddle Agedmedicine.diseasePrognosisPrimary tumorCombined Modality TherapyBevacizumabOxaliplatinSurvival RateOncologyAdenocarcinomaBiomarker (medicine)SurgeryCamptothecinFemaleFluorouracilbusinessColorectal Neoplasmsmedicine.drugFollow-Up StudiesAnnals of surgical oncology
researchProduct

Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients

2009

AIM: To investigate the efficacy and safety of cape-citabine plus irinotecan ± bevacizumab in advanced or metastatic colorectal cancer patients. METHODS: Forty six patients with previously untreated, locally-advanced or metastatic colorectal cancer (mCRC) were recruited between 2001-2006 in a prospective open-label phase II trial, in German community-based outpatient clinics. Patients received a standard capecitabine plus irinotecan (CAPIRI) or CAPIRI plus bevacizumab (CAPIRI-BEV) regimen every 3 wk. Dose reductions were mandatory from the first cycle in cases of > grade 2 toxicity. The treatment choice of bevacizumab was at the discretion of the physician. The primary endpoints were respon…

OncologyAdultMalemedicine.medical_specialtyBevacizumabgenetic structuresColorectal cancereducationKaplan-Meier EstimateAntibodies Monoclonal HumanizedGastroenterologyDeoxycytidineDisease-Free SurvivalCapecitabineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineOutpatient clinicHumansProspective StudiesAgedAged 80 and overbusiness.industryGastroenterologyAntibodies MonoclonalGeneral MedicineDrug ToleranceMiddle Agedmedicine.diseasePrimary tumordigestive system diseaseseye diseasesIrinotecanBrief ArticlesBevacizumabRegimenFluorouracilCamptothecinFemaleFluorouracilbusinessColorectal Neoplasmsgeographic locationsmedicine.drug
researchProduct

HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and che…

2013

HER2 is an established therapeutic target in breast and gastric cancers. The role of HER2 in rectal cancer is unclear, as conflicting data on the prevalence of HER2 expression in this disease have been reported. We evaluated the prevalence of HER2 and its impact on the outcome of high-risk rectal cancer patients treated with neoadjuvant CAPOX and CRT +/- cetuximab in the EXPERT-C trial. Eligible patients with available tumour tissue for HER2 analysis were included. HER2 expression was determined by immunohistochemistry (IHC) in pre-treatment biopsies and/or surgical specimens (score 0-3+). Immunostaining was scored according to the consensus panel recommendations on HER2 scoring for gastric…

OncologyAdultMalemedicine.medical_specialtyOrganoplatinum CompoundsColorectal cancerReceptor ErbB-2medicine.medical_treatmentCetuximabAdenocarcinomamedicine.disease_causeAntibodies Monoclonal HumanizedDeoxycytidineDisease-Free SurvivalCapecitabineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansSingle-Blind Methodskin and connective tissue diseasesneoplasmsNeoadjuvant therapyCapecitabineAgedProportional Hazards ModelsRetrospective StudiesCetuximabbusiness.industryRectal NeoplasmsCancerCAPOX RegimenHematologyChemoradiotherapyMiddle Agedmedicine.diseaseNeoadjuvant TherapyOxaliplatinTreatment OutcomeOncologyChemotherapy AdjuvantFemaleKRASFluorouracilbusinessChemoradiotherapymedicine.drugAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Eribulin (E) and capecitabine (C), a combined treatment schedule in elderly metastatic breast cancer (EMBC): Efficacy and safety evaluation (E&S).

2014

e20513 Background: E mesylate, a nontaxane microtubule dynamics inhibitor, was approved in the U.S in 2010 for the treatment of MBC who have previously received at least 2 MBC chemo regimens, inclu...

OncologyCancer ResearchSchedulemedicine.medical_specialtyMicrotubule dynamicsMesylatebusiness.industrybacterial infections and mycosesmedicine.diseaseMetastatic breast cancerCapecitabinechemistry.chemical_compoundCombined treatmentOncologychemistryInternal medicinepolycyclic compoundsmedicinebacteriaskin and connective tissue diseasesbusinessneoplasmsmedicine.drugEribulinJournal of Clinical Oncology
researchProduct

The impact of TP53 mutation on high-risk rectal cancer patients treated within the EXPERT-C trial, a randomized phase II study of neoadjuvant oxalipl…

2012

e14088 Background: The EXPERT-C trial randomised 165 patients into neoadjuvant CAPOX and CRT ± cetuximab and demonstrated a significant increase in radiological response (RR) and overall survival (OS) with cetuximab in KRAS/BRAF wild type (WT) rectal cancer (Dewdney et al JCO in press). TP53 mutation has been associated with worse CRT response and survival in rectal cancer and could lead to stimulation of PI3K signalling pathway, thus potential resistance to cetuximab. This analysis evaluates the impact of TP53 mutation in the EXPERT-C trial. Methods: FFPE tissue from biopsy (n=102) and resection specimens (n=99) were analysed for TP53 mutations (exons 5-8) using a multiplex PCR method fol…

OncologyCancer Researchmedicine.medical_specialtyCetuximabbusiness.industryColorectal cancerPhases of clinical researchmedicine.diseaseTp53 mutationOxaliplatinCapecitabineOncologyInternal medicinemedicineOverall survivalbusinessneoplasmsmedicine.drugJournal of Clinical Oncology
researchProduct

Combination of eribulin (E) and capecitabine (C) in elderly metastatic breast cancer (MBC): Update of a new option suitable in older elderly.

2015

9540 Background: E mesylate, a nontaxane microtubule dynamics inhibitor is widely prescribed for MBC pts pretreated with at least 1-2 lines of chemotherapy, including anthracyclines and taxanes (A&...

OncologyCancer Researchmedicine.medical_specialtyChemotherapyMicrotubule dynamicsMesylatebusiness.industrymedicine.medical_treatmentPharmacologymedicine.diseaseMetastatic breast cancerCapecitabinechemistry.chemical_compoundOncologychemistryInternal medicinemedicinebacteriabusinessmedicine.drugEribulinJournal of Clinical Oncology
researchProduct

Effects of erybuline/capecitabine (EC) treatment in very elderly women (VEW) with MBC.

2017

e12508 Background: Eribuline mesylate, is widely prescribed for MBC pts alone or in combination with Capecitabine in patients pretreated with at least 1-2 lines of chemotherapy, including anthracyclines and taxanes (A&T). Elderly Patients (EP) develop rapid and sometimes fatal toxicity during treatments due to pharmacokinetic features of these drugs.A combination schedule (E+C) to evaluate its suitability for VEW with MBC patients ,was used in this study. Methods: Treatment plan: E 0.96 mg/sqm IV on d1 every 21d - C 900 mg/sqm bid d1-14 every 28d (Dose-adjustement if necessary was according to Kintzel-Dorr’s formula for elderly), schedule administration continued until progression or i…

OncologyCancer Researchmedicine.medical_specialtyChemotherapybusiness.industryMesylatemedicine.medical_treatmentSurgeryCapecitabinechemistry.chemical_compoundOncologychemistryInternal medicinemedicineIn patientbusinessmedicine.drugJournal of Clinical Oncology
researchProduct

Metronomic Chemotherapy for Metastatic Breast Cancer.

2021

<b><i>Background:</i></b> As disease control and quality of life play a leading role in metastatic breast cancer (MBC), metronomic chemotherapy (MCT) is gaining popularity alongside conventional chemotherapy (CCT) and targeted therapies. <b><i>Summary:</i></b> MCT, defined as continuous administration of low-dose chemotherapeutic agents, is accepted as a therapy that exerts its effects via immunomodulation, anti-angiogenesis and direct cytotoxic effects. Oral administration of MCT is safe, easy to handle, and allows for flexible drug dosing. Dose accumulations associated with non-tolerable side effects are rare, so the medication can be admini…

OncologyCancer Researchmedicine.medical_specialtyCyclophosphamideReceptor ErbB-2Antineoplastic AgentsBreast NeoplasmsVinorelbinelaw.inventionCapecitabineRandomized controlled triallawOral administrationInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansCyclophosphamideCapecitabinebusiness.industryHematologymedicine.diseaseMetastatic breast cancerMetronomic ChemotherapyOncologyQuality of LifeMethotrexateFemalebusinessmedicine.drugOncology research and treatment
researchProduct

Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study

2021

Abstract Purpose Triple-negative breast cancer (TNBC) represents a subtype of breast cancer which lacks the expression of oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor-2 (HER2): TNBC accounts for approximately 20% of newly diagnosed breast cancers and is associated with younger age at diagnosis, greater recurrence risk and shorter survival time. Therapeutic options are very scarce. Aim of the present analysis is to provide further insights into the clinical activity of metronomic chemotherapy (mCHT), in a real-life setting. Methods We used data included in the VICTOR-6 study for the present analysis. VICTOR-6 is an Italian multicentre retrosp…

OncologyCancer Researchmedicine.medical_specialtyReceptor ErbB-2Breast NeoplasmsTriple Negative Breast NeoplasmsVinorelbineCapecitabine; Cyclophosphamide; Methotrexate; Metronomic chemotherapy; Triple-negative breast cancer; Vinorelbine; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cyclophosphamide; Female; Humans; Receptor ErbB-2; Retrospective Studies; Breast Neoplasms; Triple Negative Breast NeoplasmsCapecitabineErbB-2Breast cancerTriple-negative breast cancerRetrospective StudieInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProgression-free survivalCyclophosphamideTriple-negative breast cancerCapecitabineRetrospective StudiesAntineoplastic Combined Chemotherapy Protocolbusiness.industryMetronomic chemotherapyVinorelbinemedicine.diseaseClinical TrialMetronomic ChemotherapyMetastatic breast cancerRegimenMethotrexateOncologyFemalebusinessBreast NeoplasmHumanReceptormedicine.drug
researchProduct

Metronomic therapy irinotecan (IRI) capecitabine (CAP) plus bevacizumab (BEV) in treatment of advanced colorectal cancer (ACRC) in very elderly peopl…

2010

Background: ACRC is one of most common neoplastic disease in very old pts. The administration of oral fluoropyrimidine (capecitabine-CAP) in a standard schedule of 1,200 mg/sqm twice a day for 14 d shows similar effects to 5-FU continuous infusion (C.I.). Furthermore, CAP- IRI showed super -additive antitumor activity. Recently many study show the safety and efficacy of a "flat dose" administration of CAP particularly in the treatment of elderly people with cancer. Also, the efficacy of BEV is well demonstrated in CRC pts. Aim of the study is to evaluate impact of bevacizumab (BEV) in combination with IRI and XEL in ACRC very old patients. Methods: 42 (20 f-22 m) elderly patients with advan…

OncologyCancer Researchmedicine.medical_specialtyScheduleBevacizumabbusiness.industryNeoplastic diseaseAdvanced colorectal cancerIrinotecanCapecitabinestomatognathic diseasesOncologyInternal medicineMedicineElderly peoplebusinessgeriatric oncologyMetronomic therapymedicine.drug
researchProduct